The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | The prognostic role of MRD in follicular lymphoma
Simone Ferrero, MD, University of Turin and Hospital “Città della Salute e della Scienza di Torino”, Turin, Italy, comments on the role of measurable residual disease (MRD) as a prognostic tool in the treatment of patients with follicular lymphoma (FL). Dr Ferrero highlights the use of MRD, particularly in peripheral blood, as a predictive marker at the end of induction, during follow-up, or during maintenance with rituximab. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
